Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.864 USD | +11.68% | +8.97% | -46.03% |
May. 15 | Sector Update: Health Care Stocks Advance in Afternoon Trading | MT |
May. 15 | CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study | MT |
Financials (USD)
Sales 2024 * | 19.8M | Sales 2025 * | 46.48M | Capitalization | 50.19M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -33M | EV / Sales 2024 * | 2.54 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.08 x |
P/E ratio 2024 * |
-1.51
x | P/E ratio 2025 * |
-1.81
x | Employees | 176 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.99% |
1 day | +11.68% | ||
1 week | +8.97% | ||
1 month | +64.15% | ||
3 months | -30.88% | ||
6 months | -30.88% | ||
Current year | -46.03% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 18-08-31 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Yue Wu
BRD | Director/Board Member | 62 | 13-03-31 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 23-03-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.864 | +11.68% | 29,664 |
24-05-30 | 3.46 | -5.31% | 14,677 |
24-05-29 | 3.654 | -0.97% | 10,653 |
24-05-28 | 3.69 | +4.06% | 13,759 |
24-05-24 | 3.546 | +9.44% | 37,541 |
Delayed Quote Nasdaq, May 31, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.03% | 44.94M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- CASI Stock